Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer
Interventions: DRUG: Abiraterone Acetate|DRUG: Prednisone|DRUG: Aromatase Inhibitor
Sponsor: British Columbia Cancer Agency
Collaborators: Janssen Research & Development, LLC